Brainsway Ltd. (TASE:BRIN) today reported positive interim results in the safety and efficacy trial of its Deep TMS (transcranial magnetic stimulation) device for the treatment of multiple sclerosis.
The patients were divided into three groups. The effectiveness of the treatment was measured according to a range of variables. Brainsway said, "The researchers state that the results indicate that the device was safe and effective on multiple sclerosis patients, and may have improved the patients' fatigue."
Brainsway cautioned, however, "The effect of the treatment on metabolism and on the brain's nervous activity has not yet been tested."
Brainway executives told "Globes" in an interview that they were optimistic about the company's condition, despite a 40% drop in its share price this year.
Brainsway's share price rose 4.9% today to NIS 18.72, giving a market cap of NIS 221 million.
Published by Globes [online], Israel business news - www.globes-online.com - on December 25, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011